News For CRIS From The Last 14 Days Check below for free stories on CRIS the last two weeks.
There are 8 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 10, 2012
|
| 10:01 EDT |  | CRIS |
|
|
February 9, 2012
|
| 16:23 EDT |  | CRIS |
|
|
February 8, 2012
|
| 07:05 EDT |  | CRIS |
|
|
January 31, 2012
|
| 09:13 EDT |  | CRIS |
| theflyonthewall.com: | Curis price target raised to $7 from $5 at Summer Street | | Summer Street raised its price target for Curis shares after Erivedge received FDA approval and reiterates a Buy rating on the stock. :theflyonthewall.com |
| | 07:21 EDT | | CRIS |
|
|
January 30, 2012
|
| 15:51 EDT |  | CRIS |
| | 11:30 EDT |  | CRIS |
| theflyonthewall.com: | Curis confirms FDA approval for Erivedge | | Curis (CRIS) announced that Erivedge capsule was approved by the FDA for the treatment of adults with a type of skin cancer, called basal cell carcinoma, that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation. Erivedge is the first and only FDA-approved medicine for people with advanced forms of the most common skin cancer. It is being developed and will be commercialized by Roche (RHHBY) and Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech. Curis earned a $10M milestone payment from Genentech as a result of the FDA's approval of Erivedge in this indication and is also entitled to receive royalties on future sales of the product. :theflyonthewall.com |
| | 11:23 EDT | | CRIS |
| theflyonthewall.com: | Roche unit confirms FDA approval for Erivedge, jointly developed with Curis | | Genentech, a member of the Roche Group (RHHBY), announced that Erivedge capsule was approved by the U.S. Food and Drug Administration for the treatment of adults with a type of skin cancer, called basal cell carcinoma, that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation. Erivedge is the first FDA-approved medicine for people with advanced forms of the most common skin cancer. Roche and Genentech are also evaluating Erivedge in a Phase II trial in people with operable forms of BCC. Roche is developing Erivedge under a collaboration agreement with Curis, Inc. (CRIS) Curis is eligible to receive cash payments upon the successful achievement of specified clinical development and regulatory approval milestones, as well as royalties upon commercialization of Erivedge. :theflyonthewall.com |
|
|
|
Subscribe for More Information